Navigation Links
AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Date:5/14/2008

onstrated in Phase 2 studies to provide fast and long-lasting relief of BPH symptoms while being well tolerated, with a low incidence of sexual side effects. Cetrorelix peptide-based drugs were developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovarian stimulation/assisted reproductive technologies) in Europe, the U.S. and Japan. It was launched on the market through Serono (now Merck Serono) in the United States, Europe and in several other countries, as well as in Japan through Shionogi.

About the Cetrorelix Phase 3 Program in BPH

Cetrorelix pamoate is being studied in three Phase 3 trials which will include approximately 1,500 men with symptomatic BPH in the United States, Canada and Europe. One Phase 3 efficacy trial, primarily in the United States and Canada and with additional sites in Europe, involves approximately 600 patients (completion of patient recruitment announced on April 15, 2008) and is being led by Herbert Lepor, M.D., Professor and Martin Spatz Chairman of Urology, New York University School of Medicine, New York. In the trial, patients enter a no-treatment run-in observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (I-PSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients will receive cetrorelix by IM injection at Week 52, 54, 78 and 80 will be followed up to Week 90.

A second, similarly designed ongoing (first patient dosing announced on March 26, 2008) multi-center Phase 3 efficac
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AEterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007
2. Amarin Announces Private Placement for up to $60 Million
3. NightHawk Radiology Holdings, Inc. Announces Dutch Tender Offer for Its Common Stock
4. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
5. Veria Announces Acquisition of Massage Envy Ltd.
6. TOFUTTI Announces First Quarter Results
7. Natural Alternatives International, Inc. Announces Third Quarter Results
8. eDiets.com(R) Announces Q1 2008 Results
9. Boston Scientific Announces FDA Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results
11. The Blue Foundation for a Healthy Florida Announces $8 Million Initiative to Address Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... LOS ANGELES, Sept. 10 Award-winning actresses Edie Falco and Cynthia ... service campaign to educate cancer patients and their loved ones about ... of learning how to manage one,s risk. , , ... http://www.prnewswire.com/mnr/amgen/39907/ , , (Photo: ...
... , , , ... for cranial remolding on the road with the company,s new Mobile STAR Cranial ... shape scanning system that scans a child,s head in less than two seconds. ... wherever the unit travels, and the van is also equipped with the necessary ...
... , , , Council ... Experts at First in a Series of Briefings About Achieving "Recovery ... 10 Immigration and education policy experts gathered on Capitol Hill ... innovation. The briefing, titled Education & Immigration: The Building ...
... Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased ... order for the MammoView(TM) line of surgical endoscopy instruments ... boasts one of the most comprehensive health-care networks in ... staffed by University Physicians, offering the finest primary, secondary ...
... But not treating problems resulted in roughly same outcome, ... -- Treatment can help workers with mental health problems ... have high levels of mental stress seemed to have ... investigators looked at statistics regarding mental health and productivity ...
... , , FOSTER CITY, ... today that it has closed a $6 million series A round ... by X/Seed Capital, which also co-invested in the Series A. Concurrent ... seats on the company,s board. , , ...
Cached Medicine News:Health News:Video: Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering One's Risk of Infection During Treatment 2Health News:Video: Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering One's Risk of Infection During Treatment 3Health News:New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting-Edge Treatment to Satellite Communities 2Health News:New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting-Edge Treatment to Satellite Communities 3Health News:New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting-Edge Treatment to Satellite Communities 4Health News:New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting-Edge Treatment to Satellite Communities 5Health News:U.S. Leadership in Medical Innovation Depends on Education and Immigration Policy, Say Experts at Capitol Hill Briefing on 'Education & Immigration: Building Blocks of Innovation' 2Health News:U.S. Leadership in Medical Innovation Depends on Education and Immigration Policy, Say Experts at Capitol Hill Briefing on 'Education & Immigration: Building Blocks of Innovation' 3Health News:U.S. Leadership in Medical Innovation Depends on Education and Immigration Policy, Say Experts at Capitol Hill Briefing on 'Education & Immigration: Building Blocks of Innovation' 4Health News:Solos Endoscopy, Inc. Receives Purchase Order from One of the Major Healthcare Systems in Missouri 2Health News:Treating Workers' Mental Woes May Boost Productivity 2Health News:VitaPath Genetics Raises $6M in Series A Round 2
(Date:1/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ) ... Market (Indwelling or Foley Catheters, Intermittent Catheters and Male ... Share, Growth, Trends and Forecast 2014 - 2020" ... present, the global market for urinary catheters is experiencing ...
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
Breaking Medicine Technology:Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... PITTSBURGH , Feb. 3 An era ... together to fight cancer.  Now, drug response markers such as ... to determine individual cancer treatment plans when using various chemotherapeutic ... Inc., a life sciences company in Pittsburgh, Pennsylvania . ...
... PITTSBURGH , Feb. 3 Foundation Radiology Group ... downtown Pittsburgh , is pleased to announce its new division, ... and PET/CT imaging pioneer, Todd M. Blodgett , M.D.. ... as the Chief of Cancer Imaging at the University of ...
Cached Medicine Technology:Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions 2Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions 3Foundation Radiology Group Announces FRG Molecular Imaging Division, Led By Todd M. Blodgett, M.D. 2Foundation Radiology Group Announces FRG Molecular Imaging Division, Led By Todd M. Blodgett, M.D. 3
... IEC60601-2-51 new international standard for digital ... performance. ECG data can be reviewed ... with the optional ECG Viewer software. ... in other countries, and it truly ...
... The Stat Profile pHOx series consists of six ... and critical care profiles. Measured tests include pH, ... %, hematocrit, hemoglobin, sodium, potassium, ionized calcium, chloride, ... less than one minute. Its space saving design ...
... 25 years, Bio-logic has demonstrated continuous innovations ... introduced the first Digital EEG system brings ... you! Ceegraph VISION is the first Windows ... to integrate all your EEG needs: epilepsy ...
Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
Medicine Products: